Maryland

Enviva Supports Conclusions from New Report on “The Future of Bioenergy”

Monday, December 9, 2019 - 8:07pm

The world cannot afford to delay taking decisive climate action, and this bioenergy report is an important contribution to help define an ambitious way forward.

Key Points: 
  • The world cannot afford to delay taking decisive climate action, and this bioenergy report is an important contribution to help define an ambitious way forward.
  • During a critical time in search of the best solutions to address climate change, Enviva appreciates this thoughtful analysis on bioenergy that helps define the pathways to contain climate change below 1.5C.
  • The report makes an important contribution to the dialogue on bioenergys role as an energy source into the future, and that pathways to meet our climate goals include a key role for bioenergy.
  • The type of bioenergy we use to meet climate goals is essential, and the report makes an important distinction between land-intensive bioenergy (defined as bioenergy from terrestrial plants (e.g.

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

Monday, December 9, 2019 - 5:00pm

The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development.

Key Points: 
  • The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development.
  • Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE.
  • Nanomolar brain concentrations of KB-3061 conferred significant seizure protection in the maximal electroshock model (MES) of epilepsy with minimal impact on neurobehavior.
  • Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.

WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition

Monday, December 9, 2019 - 3:00pm

In this study, sets of matched CAR-MILs and CAR-PBLs were manufactured from the bone marrow and blood of multiple myeloma patients.

Key Points: 
  • In this study, sets of matched CAR-MILs and CAR-PBLs were manufactured from the bone marrow and blood of multiple myeloma patients.
  • This superiority continued even upon repeated antigen encounters which could translate into better anti-tumor efficacy and persistence.
  • Importantly, CAR-MILs demonstrated a greater degree of cytokine and chemokine secretion consistent with a more polyfunctional cytokine profile.
  • Taken together, these are key criteria to enhancing the therapeutic benefit of CAR-T cells and underscore the marked differences between CAR-MILs and CAR-PBLs.

GSE Systems Announces Renewal of Specialty Engineer of Choice Contract for Additional Three Years

Monday, December 9, 2019 - 2:00pm

GSE True North, part of the GSE Systems group, specializes in plant thermal performance and engineering programs to optimize plant performance and safety.

Key Points: 
  • GSE True North, part of the GSE Systems group, specializes in plant thermal performance and engineering programs to optimize plant performance and safety.
  • This SEOC agreement renewal provides GSE True North priority to support the clients engineering programs and other specialty services and products on an as needed basis.
  • This SEOC renewal serves as a continued vote of confidence from a major client, said Kyle Loudermilk, president and chief executive officer of GSE Systems.
  • GSE Systems, Inc. is a leading provider of engineering, expert staffing and simulation software to clients in the power and process industries.

Immunocore announces dosing of first patient with third ImmTAC® bispecific

Monday, December 9, 2019 - 12:00pm

Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the companys innovative ImmTAC technology platform.

Key Points: 
  • Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announced the start of the first-in-human clinical trial of IMC-C103C, the third bispecific developed using the companys innovative ImmTAC technology platform.
  • The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.
  • David Berman, Head of Research and Development at Immunocore, commented: We have now brought our third TCR- engineered bispecific ImmTAC into the clinic.
  • Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA.

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy

Sunday, December 8, 2019 - 3:00pm

The data are being presented today during a poster presentation session at the American Epilepsy Society (AES) 2019 Meeting in Baltimore.

Key Points: 
  • The data are being presented today during a poster presentation session at the American Epilepsy Society (AES) 2019 Meeting in Baltimore.
  • We look forward to advancing the clinical development program of CVL-865 as we proceed to a Phase 2 trial in patients with drug-resistant focal onset seizures.
  • CVL-865 is a novel 2/3/5-subtype selective GABAA receptor positive allosteric modulator.
  • Approximately 65 million people worldwide suffer from epilepsy, according to the Epilepsy Foundation, and it affects people of all ages.

Nihon Kohden Donates to Epilepsy Research for 11th Consecutive Year

Saturday, December 7, 2019 - 7:00pm

Nihon Kohden, a leader in epilepsy and neurology instrumentation, established the donation program more than a decade ago to foster future advancements in epilepsy diagnosis and treatment.

Key Points: 
  • Nihon Kohden, a leader in epilepsy and neurology instrumentation, established the donation program more than a decade ago to foster future advancements in epilepsy diagnosis and treatment.
  • Nihon Kohden's ongoing contributions to epilepsy research have supported promising research of several new investigators, said Page B. Pennell, MD, president of the American Epilepsy Society.
  • We appreciate Nihon Kohden's commitment to research and are pleased to celebrate 11 years of continued partnership.
  • Nihon Kohdens support of AES is part of the organizations fundraising efforts to support the societys educational, research and training offerings.

Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

Saturday, December 7, 2019 - 5:00pm

EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible.

Key Points: 
  • EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible.
  • What is particularly remarkable is that these data were generated from a spontaneous seizure model, which we believe accurately reflects the clinical situation in people with Dravet syndrome.
  • Dravet syndrome is a severe and progressive genetic epilepsy that begins within the first year of life.
  • In the studies presented in todays poster, the efficacy of STK-001 was evaluated in a Scn1a-linked mouse model of Dravet syndrome that results in Nav1.1 haploinsufficiency.

Kindred Nutrition and Wellness expands services to act as a "one stop shop" for overall health

Friday, December 6, 2019 - 9:15pm

FREDERICK, Md., Dec. 6, 2019 /PRNewswire-PRWeb/ -- Kindred Nutrition and Wellness, owned by Amy Goldsmith, Dietitian, is happy to announce an expansion in services.

Key Points: 
  • FREDERICK, Md., Dec. 6, 2019 /PRNewswire-PRWeb/ -- Kindred Nutrition and Wellness, owned by Amy Goldsmith, Dietitian, is happy to announce an expansion in services.
  • While Kindred Nutrition and Wellness will continue to focus on Specialized Medical Nutrition Therapy and Sports Nutrition and Performance, counseling they are now happy to offer Individual and Family Therapy and Yoga.
  • Kindred Nutrition and Wellness has three dietitians specializing in Autoimmune Disorders, Gastrointestinal Disorders, Renal Disease, Eating Disorders, and Sports Nutrition.
  • To get more information about Kindred Nutrition and Wellness check out their website out at http://www.kindrednutrition.com or call 301-580-0008.

FDA sends warning to companies for offering unapproved umbilical cord blood products that may put patients at risk

Friday, December 6, 2019 - 8:25pm

The companies' unapproved products derived from umbilical cord blood are PURE and PURE PRO.

Key Points: 
  • The companies' unapproved products derived from umbilical cord blood are PURE and PURE PRO.
  • In addition to the warning letter issued to Liveyon Labs and Liveyon LLC earlier this month, the FDA sent untitled letters to RichSource Stem Cells, Inc., and Chara Biologics, Inc. , for offering unapproved stem cell products to patients.
  • "The FDA's mission includes protecting public health by helping to ensure the safety and efficacy of medical products that patients rely on.
  • The FDA monitors these reports and takes appropriate action necessary to ensure the safety of medical products in the U.S. marketplace.